Pseudotyped viral particles for targeting tcr-expressing cells
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsChristos KYRATSOUS, Andrew J. MURPHY, Mathieu DESCLAUX, Augustine CHOY
Life of this patent
Estimating the term…
Abstract
Described herein are pseudotyped viral particles for specific targeting of TCR-expressing cells and the use of such particles for treatment of various diseases.
Claims186
A recombinant viral particle that is capable of binding to a T cell receptor (TCR), the recombinant viral particle comprising on its surface a TCR-binding molecule.
A recombinant viral particle that is capable of binding to an antigen-specific T-cell receptor (TCR), the recombinant viral particle comprising on its surface a peptide (p) presented in the context of a major histocompatibility complex (MHC) molecule (pMHC complex).
A method of producing a viral particle that is capable of binding to a T-cell receptor (TCR), said method comprising culturing a packaging cell in conditions sufficient for the production of a plurality of viral particles, wherein the packaging cell comprises one or more plasmids comprising (i) one or more viral elements involved in the assembly of the viral particle, and (ii) a nucleotide sequence encoding a TCR-binding molecule.
A method of producing a viral particle that is capable of binding to an antigen-specific T-cell receptor (TCR), said method comprising culturing a packaging cell in conditions sufficient for the production of a plurality of viral particles, wherein the packaging cell comprises one or more plasmids comprising (i) one or more viral elements involved in the assembly of the viral particle, (ii) a nucleotide sequence encoding a peptide, and (iii) one or more nucleotide sequence(s) encoding a major histocompatibility complex (MHC) molecule, wherein the viral particles present the antigen-derived peptide in the context of the MHC.
Dependencies are inferred from the claim text.